- \n
- Phytocannabinoid study \u2013 strains, chemovars, entourage and molecules<\/span><\/li>\n
- Pharamacokinetics and pharmacodynamics of cannabinoids<\/span><\/li>\n
- Clinical cannabinoid therapy across medical specialties; Pain, Gastroenterology, Palliative Care, Psychiatry and Neurology<\/span><\/li>\n
- New designs for cannabis clinical trials (including pragmatic trials and n=1)<\/span><\/li>\n
- Clinical Registries<\/span><\/li>\n
- Observational \/ Epidemiological studies: findings, interpretations, plans<\/span><\/li>\n
- Phase 2\/3\/4 study findings and designs (including special populations<\/span><\/li>\n
- Meta- and composite- analyses: findings and methodology<\/span><\/li>\n
- Regulatory, licensing, and development program issues and plans<\/span><\/li>\n
- Cannabinoid trial best conduct including GCP and site training<\/span><\/li>\n
- Assessing safety and adverse events of cannabinoid medications<\/span><\/li>\n
- Clinical trials with psychedelics, theory and practice<\/span><\/li>\n<\/ul>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"
Phytocannabinoid study \u2013 strains, chemovars, entourage and molecules Pharamacokinetics and pharmacodynamics of cannabinoids Clinical cannabinoid therapy across medical specialties; Pain, Gastroenterology, Palliative Care, Psychiatry and Neurology New designs for cannabis clinical trials (including pragmatic trials and n=1) Clinical Registries Observational \/ Epidemiological studies: findings, interpretations, plans Phase 2\/3\/4 study findings and designs (including special populations […]<\/p>\n","protected":false},"author":6,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_acf_changed":false,"footnotes":""},"class_list":["post-479","page","type-page","status-publish","hentry"],"acf":[],"yoast_head":"\n
Abstract Topics - CT-Cann2024<\/title>\n\n\n\n\n\n\n\n\n\n\n\n\n\t\n - Pharamacokinetics and pharmacodynamics of cannabinoids<\/span><\/li>\n
\n